Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2024; 12(20): 4082-4090
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4082
Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer
Jian He, Yi-Pu Zhong, Shuang Zhang
Jian He, Shuang Zhang, Department of Nuclear Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
Yi-Pu Zhong, Department of Nuclear Medicine, The People’s Hospital of Jianyang, Jianyang 641400, Sichuan Province, China
Author contributions: He J performed the majority of experiments and wrote the manuscript; Zhong YP designed the study and revised the manuscript; Zhang S was involved in the analytical tools; He J and Zhong YP participated in the collection of the human material; He J and Zhang S served as scientific advisors; Zhong YP was the guarantor.
Institutional review board statement: The research was reviewed and approved by the Review Committee of Hospital of Chengdu University of Traditional Chinese Medicine (Approval No. HCUTCM-23-976).
Informed consent statement: All research participants or their legal guardians provided written informed consent prior to study registration.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No other data available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shuang Zhang, MAMS, Doctor, Department of Nuclear Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shierqiao Road, Chengdu 610072, Sichuan Province, China. shudufeiji7177441@163.com
Received: March 9, 2024
Revised: May 14, 2024
Accepted: June 3, 2024
Published online: July 16, 2024
Processing time: 113 Days and 18.4 Hours
Core Tip

Core Tip: This work investigated the diagnostic value of technetium-99m-methylene diphosphonate (99mTc-MDP) single photon emission computed tomography (SPECT)/ CT imaging combined with the serum prostate-specific antigen (PSA)/free PSA ratio for detecting bone metastasis in prostate cancer (PC). Compared to individual methods, the combination of SPECT/CT imaging and PSA/fPSA ratio demonstrated significantly higher positive predictive values and specificity. The PSA/fPSA ratio in PC bone metastasis (PCBM) patients was notably lower than in non-PCBM patients. The integrated approach achieved a 95% detection rate for PCBM, emphasizing its diagnostic efficacy.